{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:46Z","timestamp":1786119406791,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/md.0000000000002763","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T07:42:41Z","timestamp":1455262961000},"page":"e2763","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia"],"prefix":"10.1097","volume":"95","author":[{"given":"Chi-Chuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-70-20210509","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"key":"R2-70-20210509","first-page":"279","article-title":"Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006.","volume":"40","year":"2007","journal-title":"J Microbiol Immunol Infect"},{"key":"R3-70-20210509","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1055\/s-0032-1315635","article-title":"Antibiotic resistance of pathogens causing community-acquired pneumonia","volume":"33","author":"Feldman","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"key":"R4-70-20210509","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000079816","article-title":"Comparative antimicrobial susceptibility of respiratory tract pathogens","volume":"50","author":"Felmingham","year":"2004","journal-title":"Chemotherapy"},{"key":"R5-70-20210509","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2010.04.013","article-title":"Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia","volume":"36","author":"Jones","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R6-70-20210509","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.idc.2012.11.013","article-title":"What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?)","volume":"27","author":"Low","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"R7-70-20210509","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0732-8893(02)00445-5","article-title":"Fluoroquinolones for the treatment of outpatient community-acquired pneumonia","volume":"44","author":"Jones","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R8-70-20210509","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"179","author":"Vardakas","year":"2008","journal-title":"CMAJ: Can Med Assoc J"},{"key":"R9-70-20210509","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11585310-000000000-00000","article-title":"Bacteraemic pneumococcal pneumonia: current therapeutic options","volume":"71","author":"Feldman","year":"2011","journal-title":"Drugs"},{"key":"R10-70-20210509","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1185\/03007990902779749","article-title":"Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750\u200amg daily versus ceftriaxone 1000\u200amg plus azithromycin 500\u200amg daily: a US-based study","volume":"25","author":"Frei","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R11-70-20210509","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"key":"R12-70-20210509","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-70-20210509","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-005-1347-1","article-title":"Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors","volume":"24","author":"Portier","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R14-70-20210509","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2004.07.013","article-title":"Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization","volume":"25","author":"Querol-Ribelles","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R15-70-20210509","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.idc.2012.11.004","article-title":"Does empirical therapy with a fluoroquinolone or the combination of a beta-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?","volume":"27","author":"Ruhe","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"R16-70-20210509","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1378\/chest.128.2.940","article-title":"The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia","volume":"128","author":"Weiss","year":"2005","journal-title":"Chest"},{"key":"R17-70-20210509","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.clinthera.2008.01.023","article-title":"Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis","volume":"30","author":"Ye","year":"2008","journal-title":"Clin Ther"},{"key":"R18-70-20210509","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"R19-70-20210509","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R20-70-20210509","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3201\/eid1103.040819","article-title":"Antimicrobial drug prescribing for pneumonia in ambulatory care","volume":"11","author":"MacDougall","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R22-70-20210509","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/ki.2014.79","article-title":"Pneumococcal pneumonia infection is associated with end-stage renal disease in adult hospitalized patients","volume":"86","author":"Huang","year":"2014","journal-title":"Kid Int"},{"key":"R23-70-20210509","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"R24-70-20210509","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00002512-200825070-00005","article-title":"Improving outcomes of elderly patients with community-acquired pneumonia","volume":"25","author":"Gutierrez","year":"2008","journal-title":"Drugs Aging"},{"key":"R25-70-20210509","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00002512-200017020-00002","article-title":"Community-acquired pneumonia in the elderly: a practical guide to treatment","volume":"17","author":"Lieberman","year":"2000","journal-title":"Drugs Aging"},{"key":"R26-70-20210509","first-page":"3","article-title":"Management of community-acquired pneumonia in older adults","volume":"2","author":"Simonetti","year":"2014","journal-title":"Ther Adv Infect dis"},{"key":"R28-70-20210509","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/AAC.05658-11","article-title":"Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study","volume":"56","author":"Kim","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-70-20210509","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/jac\/dkp209","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000\u201307: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18","volume":"64","author":"Su","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R30-70-20210509","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jmii.2012.07.012","article-title":"Updated antibiotic resistance and clinical spectrum of infections caused by Streptococcus pneumoniae in Taiwan: emphasis on risk factors for penicillin nonsusceptibilities","volume":"46","author":"Tsai","year":"2013","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000002763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:12Z","timestamp":1786039872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201602090-00070"}},"subtitle":["A Nationwide Population-Based Cohort Study"],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002763","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}